Latest Healthcare News

Talius Group appoints seasoned executive Pat Howard as CEO, with founder Graham Russell shifting to a strategic growth role, signalling a new phase of expansion and innovation.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Audeara Limited has secured its largest-ever Australian wholesale purchase order worth $560,000, driving year-to-date wholesale revenues to $1.75 million and matching full FY25 figures. The company is also expanding manufacturing into China, signaling growing international ambitions.

Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.

Stakk Limited has secured a significant multi-year agreement with Panacea Financial, a U.S. neobank division backed by Peter Thiel, to provide its Embedded Finance technology. This partnership marks a strategic expansion into niche medical financial services.

Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

Pro Medicus has disclosed a contained data breach involving unauthorized access to a single employee email inbox, with limited exposure of personal information from around 100 current and former employees.

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.

Regis Healthcare has agreed to sell two aged care homes in Far North Queensland to Ozcare, securing a $25 million pre-tax gain and signaling a strategic portfolio shift towards premium locations.